About this Research Topic
Epidermal growth factor (EGF), fibroblast growth factor (FGF), Hedgehog (HH), nerve growth factor (NGF), vascular endothelial growth factor (VEGF) and WNT signaling cascades are representative oncodevelopmental signaling pathways that are involved in fetal development and adult-tissue homeostasis through determination of cell fate and regulation of cell adhesion, migration, metabolism, proliferation and survival.
Hyperactivation of oncodevelopmental pathways based on genetic and epigenetic alterations as well as intratumor communication among cancer, immune and stromal cells elicit and promote tumorigenesis. Therapeutic targeting of these pathways using small-molecule compounds, peptide-based drugs, antibody-based drugs and engineered immune cells are promising strategy for the treatment of cancer patients.
Hypoactivation of oncodevelopmental pathways cause neurodegeneration owing to the loss of neural protection. Therapeutic activation of oncodevelopmental pathways for patients with neurodegenerative diseases might prevent neural damage but fuel expansion of latent tumors in elderly patients. On the other hand, therapeutic inhibition of oncodevelopmental pathways for cancer patients can eliminate tumors but induce neural adverse effects, such as iatrogenic neuropathy.
Comprehensive understanding of oncodevelopmental pathways in neurodegeneration and tumorigenesis is required for successful drug development, because therapeutic intervention of oncodevelopmental pathways exerts yin and yang effects depending on pathological context. Therefore, we launch this Research Topic as the first step to boost interaction of neurologists and oncologists for the implementation of precision medicine in the future. Research articles, editorials, mini reviews and full reviews on oncodevelopmental signaling in neurodegeneration or tumorigenesis are welcome for submission.
Hyperactivation of oncodevelopmental pathways based on genetic and epigenetic alterations as well as intratumor communication among cancer, immune and stromal cells elicit and promote tumorigenesis. Therapeutic targeting of these pathways using small-molecule compounds, peptide-based drugs, antibody-based drugs and engineered immune cells are promising strategy for the treatment of cancer patients.
Hypoactivation of oncodevelopmental pathways cause neurodegeneration owing to the loss of neural protection. Therapeutic activation of oncodevelopmental pathways for patients with neurodegenerative diseases might prevent neural damage but fuel expansion of latent tumors in elderly patients. On the other hand, therapeutic inhibition of oncodevelopmental pathways for cancer patients can eliminate tumors but induce neural adverse effects, such as iatrogenic neuropathy.
Comprehensive understanding of oncodevelopmental pathways in neurodegeneration and tumorigenesis is required for successful drug development, because therapeutic intervention of oncodevelopmental pathways exerts yin and yang effects depending on pathological context. Therefore, we launch this Research Topic as the first step to boost interaction of neurologists and oncologists for the implementation of precision medicine in the future. Research articles, editorials, mini reviews and full reviews on oncodevelopmental signaling in neurodegeneration or tumorigenesis are welcome for submission.
Keywords: signaling cascades, oncodevelopmental, fetal development, adult tissue homeostasis, tumorigenesis, therapeutic targeting
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
